MAIA | MAIA Biotechnology, Inc. Stock Overview

(Stock Exchange: AMEX)

Day's Range	2.8500 - 3.15
52 Week Range	0.8200 - 5.99
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	99,036
Average Volume	160,043
Shares Outstanding	23,907,211
Market Cap	70,167,664
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-07-28

Valuation
Profitability
Growth
Health
P/E Ratio	-1.81
Forward P/E Ratio	N/A
EPS	-1.62
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	13
Country	USA
Website	MAIA

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

MAIA's peers: LCTX, PRTG, PLUR, ARMP, FREQ, AGE, LRMR, GRPH, LYRA, GNLX, CMRA, DYAI, CING, MNPR, TRGNF, EPRXF, CSBR, LUMO, ROIVW, FTHWF, TLPPF, NAUT

*Chart delayed

Analyzing fundamentals for MAIA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see MAIA Fundamentals page.

Watching at MAIA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on MAIA Technicals page.